Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells

Journal of Drug Targeting

Volumn 12, Issue 7, 2004, Pages 461-471

  Wartlick, Heidrun ^a   Michaelis, Kerstin ^a   Balthasar, Sabine ^a   Strebhardt, Klaus ^a   Kreuter, Jörg ^a   Langer, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Anti HER2 antibody; Drug targeting; Gelatin; Human serum albumin (HSA); Nanoparticles; Tumour therapy

Indexed keywords

AVIDIN; BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATIN; HUMAN SERUM ALBUMIN; NANOPARTICLE; NEUTRAVIDIN; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; BIOTINYLATION; BREAST ADENOCARCINOMA; CELL SURFACE; CELL TRANSPORT; COMPLEX FORMATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES; BIOTIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FLOW CYTOMETRY; GELATIN; GENES, ERBB-2; HUMANS; IMMUNOTOXINS; MICROSCOPY, CONFOCAL; MICROSPHERES; NEOPLASMS; SERUM ALBUMIN;

EID: 9444221978     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400010697     Document Type: Article

References (26)

1. Ahmad, I., Longenecker, M., Samuel, J. and Allen, T.M. (1993) "Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice", Cancer Res. 53, 1484-1488.
2. Akasaka, Y., Ueda, H., Takayama, K., Machida, Y. and Nagai, T. (1988) "Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies", Drug Design Deliv. 3, 85-97.
3. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. and Mendelsohn, J. (1998) "Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts", Cancer Res. 58, 2825-2831.
4. Bourel, D., Rolland, A., Le Verge, R. and Genetet, B. (1988) "A new immunoreagent for cell labeling - CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles", J. Immunol. Methods 106, 161-167.
5. Coester, C.J., Langer, K., van Briesen, H. and Kreuter, J. (2000) "Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake", J. Microencapsul. 17, 187-193.
6. Kada, G., Falk, H. and Gruber, H.J. (1999) "Accurate measurement of avidin and streptavidin in crude biofluids with a new, optimized biotin-fluorescein conjugate", Biochim. Biophys. Acta 1427, 33-43.
7. Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., Li, W.L., Carter, P., Benz, C.C. and Papahadjopoulos, D. (1997) "Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro", Biochemistry 36, 66-75.
8. Langer, K., Coester, C., Weber, C., von Briesen, H. and Kreuter, J. (2000) "Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid", Eur. J. Pharm. Biopharm. 49, 303-307.
9. Lewis, G.D., Figari, I., Fendly, B., Wong, W.L., Carter, P., Gorman, C. and Shepard, H.M. (1993) "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies", Cancer Immunol. Immunother. 37, 255-263.
10. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000) "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review", J. Control. Release 65, 271-284.
11. Nielsen, U.B. and Marks, J.D. (2000) "Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries", Pharm. Sci. Technol. Today 3, 282-291.
12. Nielsen, U.B., Kirpotin, D.B., Pickering, E.M., Hong, K., Park, J.W., Refaat Shalaby, M., Shao, Y., Benz, C.C. and Marks, J.D. (2002) "Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis", Biochim. Biophys. Acta 1591, 109-118.
13. Park, J.W., Kirpotin, D.B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U.B., Marks, J.D., Papahadjopoulos, D. and Benz, C.C. (2001) "Tumor targeting using anti-HER2 immunoliposomes", J. Control. Release 74, 95-113.
14. Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues", Oncogene 5, 953-962.
15. Rhaese, S., von Briesen, H., Rübsamen-Waigmann, H., Kreuter, J. and Langer, K. (2003) "Human serum albumin-polyethylenimine nanoparticles for gene delivery", J. Control. Release 92, 199-208.
16. Rolland, A., Bourel, D., Genetet, B. and Le Verge, R. (1987) "Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes", Int. J. Pharm. 39, 173-180.
17. Santra, S., Zhang, P., Wang, K., Tapec, R. and Tan, W. (2001) "Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers", Anal. Chem. 73, 4988-4993.
18. Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R. and Rudzinski, W.E. (2001) "Biodegradable polymeric nanoparticles as drug delivery devices", J. Control. Release 70, 1-20.
19. Spänkuch, B., Matthess, Y., Knecht, R., Zimmer, B., Kaufmann, M. and Strebhardt, K. (2004) "Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1", J. Natl Cancer Inst. 96, 862-872.
20. Sugano, M., Egilmez, N.K., Yokota, S.J., Chen, F.A., Harding, J., Huang, S.K. and Bankert, R.B. (2000) "Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice", Cancer Res. 60, 6942-6949.
21. Waelti, E., Wegmann, N., Schwaninger, R., Wetterwald, A., Wingenfeld, C., Rothen-Rutishauser, B. and Gimmi, C.D. (2002) " Targeting HER-2/neu with antirat Neu virosomes for cancer therapy", Cancer Res. 62, 437-444.
22. Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., Kreuter, J. and Langer, K. (2004) "Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles", J. Control. Release 96, 483-495.
23. Weber, C., Coester, C., Kreuter, J. and Langer, K. (2000a) "Desolvation process and surface characterisation of protein nanoparticles", Int. J. Pharm. 194, 91-102.
24. Weber, C., Reiss, S. and Langer, K. (2000b) "Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups", Int. J. Pharm. 211, 67-78.
25. Wilchek, M. and Bayer, E.A. (1990) "Biotin-containing reagents", Methods Enzymol. 184, 123-138.
26. Zhang, Y., Jeong Lee, H., and Pardridge, W.M. (2002) "Receptor-mediated delivery of an antisense gene to human brain cancer cells", J. Gene Med. 4, 183-194.